Objectives: To characterize MDR Escherichia coli from bloodstream infections (BSIs) in Australia, New Zealand and Singapore.
Introduction
In recent decades, resistance to b-lactam antibiotics in Enterobacteriaceae has become increasingly common. Of particular concern has been the rising prevalence of resistance to thirdgeneration cephalosporins (3GCs), a class that includes key agents such as ceftriaxone, cefotaxime or ceftazidime. [1] [2] [3] This phenomenon has largely arisen from the dissemination of genes encoding ESBL or, less frequently, plasmid-mediated AmpC (p-AmpC) enzymes. [4] [5] [6] These resistance genes are often acquired by plasmid transfer and may be associated with other antibiotic resistance determinants, rendering organisms MDR. 7 The global emergence of infections caused by ESBL-producing Escherichia coli, in both the community and hospital setting, has been driven by the acquisition of CTX-M-type ESBL genes (especially bla CTX-M-15 ) in the successful pandemic clone of E. coli, sequence type 131 (ST131). [8] [9] [10] [11] E. coli ST131 lineages belong to the B2 phylogenetic subgroup I, and are mostly serotype O25b:H4. 12 Within ST131, further sublineages have been delineated according to fimH (type 1 fimbrial adhesin, FimH) alleles, phylogenetic clades (A, B, C1 and C2) and associated resistance genes. 8, 13 A globally dominant fluoroquinoloneresistant fimH30 subclonal lineage, defined as H30-R (to differentiate from the ancestral fluoroquinolone susceptible H30 strains) or clade C, has been described. 8, 14 H30-R/clade C strains contain fluoroquinolone resistance mutations in the chromosomal gyrA and parC genes 15 and have been associated with poor clinical outcomes. 16 Within this sublineage, a pathogenic ST131 subclone containing bla CTX-M-15 has been referred to as H30-Rx 14 or clade C2. 8 Specific Incompatibility (Inc) F-type plasmids have also been described in association with fluoroquinolone-resistant ST131-H30 clades, with IncF-type F1:A2:B20 plasmids associated with the H30-R/C1 clade and IncF-type F2:A1:B-plasmids associated with the H30-Rx/C2 clade. [17] [18] [19] Resistance to b-lactams mediated by ESBLs drives the use of broader-spectrum antibiotics such as carbapenems (e.g. meropenem), 4 providing selection pressure for carbapenem resistance in Gram-negative bacteria. Of great concern has been the emergence of transmissible carbapenemases in common Enterobacteriaceae. 20 As part of an international randomized controlled trial of piperacillin/tazobactam (a potential 'carbapenemsparing' agent) versus meropenem for the treatment of 3GC-resistant (3GC-R) E. coli causing bloodstream infection (BSI), 21 we aimed to further characterise these isolates using WGS. 21 All initial 3GC-R E. coli blood culture isolates (i.e. the first positive culture prompting study inclusion) were included from 70 patients enrolled in the trial for the first 18 months of recruitment (from February 2014 until August 2015) from eight hospital sites in three countries [Australia (n " 21), New Zealand (n " 5) and Singapore (n " 44)]. To be eligible for the trial, patients had to have at least one monomicrobial blood culture growing E. coli, with nonsusceptibility to ceftriaxone, ceftazidime or cefotaxime and susceptibility to piperacillin/tazobactam and meropenem, determined by methods used in the local laboratories. All blood culture isolates from patients meeting inclusion criteria who consented to participate in the study were stored at the recruiting site laboratory at #80 C in cryovials containing glycerol and nutrient broth and later shipped to the coordinating laboratory in Queensland, Australia. For the purposes of this study, only the first 3GC-R E. coli isolated from blood cultures for each enrolled patient were included in the genomic analysis. Relevant clinical data were collected and managed using the REDCap 22 electronic data capture tool hosted at the University of Queensland. Healthcare-associated infection (HAI) was defined as a positive blood culture collected in a patient within 48 h of hospital admission, if the patient had received specialized nursing care at home (e.g. intravenous therapy, wound care), attended a hospital, haemodialysis unit, or received intravenous chemotherapy in the 30 days prior to the BSI event, was a resident of a nursing home or long-term care facility or had been admitted to an acute care facility for .48 h in the preceding 90 days. 23 HAI also included nosocomial bacteraemia occurring .48 h following hospital admission. BSI was defined as community associated if it occurred within 48 h of admission and the patient did not meet any criteria for HAI. 
Methods

Bacterial isolates and clinical data
Phenotypic susceptibility testing
All isolates were tested at the coordinating laboratory against a standard panel of antibiotics used to treat Gram-negative infections by disc diffusion according to EUCAST standards. 24 Agents tested included ceftriaxone, ceftazidime, cefepime, cefoxitin, aztreonam, ertapenem, gentamicin, amikacin, ciprofloxacin, co-trimoxazole and amoxicillin/clavulanate. In addition, MICs of piperacillin/tazobactam, meropenem (the two comparator drugs used in the trial) and ceftriaxone were determined by Etest (bioMérieux). ESBL production was confirmed using combination disc testing with ceftriaxone and ceftazidime with and without clavulanate; an increase in zone diameter 5 mm with the addition of clavulanate confirmed ESBL production. 25 
DNA extraction and library preparation
After subculture onto LB agar to check for viability and purity, genomic DNA was extracted using the MoBio Ultrapure kit and quantified by spectrophotometry (NanoDrop; ThermoFisher) and fluorometry (Qubit; ThermoFisher). Paired-end DNA libraries were prepared using the Nextera kit (Illumina; Australia) in accordance with the manufacturer's instructions.
WGS
WGS was performed in two batches using Illumina HiSeq (100 bp paired end) and MiSeq (300 bp paired end) at the Australian Genome Research Facility (AGRF), University of Queensland, St Lucia. MiSeq raw reads were trimmed conservatively to 150 bp and filtered using Nesoni (version 0.130) to remove Illumina adaptor sequences, reads ,80 bp and bases below Phred quality 5 (https://github.com/Victorian-Bioinformatics-Consortium/ nesoni). Strains were checked for contamination using Kraken (0.10.5-beta) as implemented through Nullarbor (default settings). 26 Resistance gene detection, MLST and plasmid typing Antibiotic resistance genes were detected by using Abricate (version 0.2) with the ResFinder database against SPAdes assemblies (version 3.6.2) as WGS of ESBL-or AmpC-producing E. coli JAC implemented through the pipeline analysis tool Nullarbor (default settings). 26 MLST was undertaken using the mlst tool as implemented through Nullarbor. Plasmid replicon typing and plasmid multilocus typing were performed using PlasmidFinder and pMLST. 27 
Fluoroquinolone resistance SNP detection
Filtered reads were mapped to the complete ST131 E. coli reference strain EC958 (GenBank: HG941718.1) using Bowtie as implemented through Nesoni. Non-synonymous mutations were identified using Nesoni nway and manually compared with known mutations in gyrA and parC associated with quinolone resistance.
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Phylogenetic analysis
Reads for all isolates (n " 70) were mapped to the complete ST131 reference EC958 (GenBank: HG941718.1) 29 using Nesoni under default settings. SNPs identified between isolates and the reference EC958 were used to create pseudogenomes for each isolate by substituting the relevant SNPs into the EC958 chromosome using an in-house script. Multiple sequence alignment of the pseudogenomes was used as input for Gubbins (version 1.3.4) 30 using the (GTR)GAMMA substitution model to parse recombinant regions. The remaining 211920 SNPs were used to generate a phylogenetic tree using RAxML (version 8.2.9) 31 under the (GTR)GAMMA substitution model with Lewis ascertainment bias correction and a random seed of 456 (100 bootstraps). An ST131-only tree (n " 43) was also created in the same manner using 2248 recombination-free SNPs and 1000 bootstraps. In silico phylo-grouping for all STs was undertaken according to the updated Clermont scheme. 32 Phylogenetic trees and associated metadata were visualized using Evolview. 33 
Sequence data
Raw sequence reads and associated metadata have been uploaded to NCBI (Bioproject Accession no. PRJNA398288). A full description of clinical metadata, MLST, acquired resistance genes and plasmid typing is available online at Harvard Dataverse (doi: 10.7910/DVN/YC9WDV).
Statistical tests
Data describing patient demographics, phenotypic susceptibility, clinical variables and genotypic data for all cases were tabulated, with proportions expressed as percentages and median, mean or IQR calculated as appropriate for scale variables. Categorical variables were compared using Pearson's v 2 test.Comparisons of mean values in normally distributed data were compared using the t-test. The Mann-Whitney U-test was used for non-parametric data. Statistical analysis was performed using Stata version 13.1 (StataCorp; TX, USA) and graphical images prepared using Prism version 7.0 (GraphPad Software; CA, USA). A P value ,0.05 was considered significant.
Results
Baseline clinical data
A total of 70 3GC-R E. coli bloodstream isolates were included. The background clinical and demographic details of enrolled patients are summarized in Table 1 . The source of BSI was most frequently the urinary tract (48/70, 69.6%) and infections were mostly community associated (44/70, 62.9%). There was a predominance of patients reporting Chinese ethnicity (38/70, 54.3% of all cases), reflecting the demographics of the largest recruiting sites in Singapore. There was also a greater proportion of male patients (60%), but this was not statistically significant (P " 0.12). Patients tended to be older (median age 71, IQR 64-81 years, range 20-94 years), although only a small proportion (5.8%) were admitted from nursing homes. The majority of patients had less severe acute illness (median Pitt score 1, IQR 0-2, range 0-3; where a score 4 reflects the presence of critical illness with high mortality 34 ) and relatively low comorbidity scores (Charlson score median 2, IQR 1-4, range 0-11) and were infrequently admitted to the ICU (3.1%). 50 32 mg/L). Two strains, which were susceptible to ceftriaxone by MIC, were resistant to ceftazidime [one (MER-15) contained bla DHA-1 , the other (MER-100) had changes to the ampC promotor region, discussed in detail later]. Phenotypic resistance to 3GCs could not be detected in one strain (MER-34) when Table 2 ), but were frequently resistant to trimethoprim/sulfamethoxazole (46/70, 65.7%) or fluoroquinolones (52/70, 74.3%). There was universal resistance to ciprofloxacin in clade C1/C2 ST131 (n " 36), compared with only 50% (3/6) and 48.2% (13/27) in clade A and non-ST131 strains, respectively (P , 0.001). A phylogenetic tree of all 3GC-R E. coli strains can be found in Figure S2 . All clade A ST131 were community associated, with a mixture of community-and healthcare-associated infections observed for strains in clades C1 and C2. There was evidence of clustering of closely related paired strains (with ,10 core genome SNPs different) within certain hospitals (e.g. MER-27/25 in Hospital E; MER-8/10 and MER-37/39 in Hospital A; Figure 2) , indicating a direct relationship or very recent transmission, although these represented both community-and healthcare-associated infections.
Antibiotic resistance phenotypes
MLST and ST131 phylogeny
Two of the Australian strains (MER-2 and MER-4) were both ST963, with chromosomally integrated bla CMY-2 , and occurred in patients whose admissions overlapped in the same hospital. However, they were separated by .350 SNPs, suggesting a more distant common ancestor.
Antibiotic resistance genes
The median number of acquired antibiotic resistance genes detected for each isolate was 9. One strain (MER-90) possessed a total of 17 acquired resistance genes, including b-lactamases (bla CMY-2 , bla TEM-1B ), aminoglycoside resistance genes [aac(3)-IIdlike, aadA1-like, aadA2, aph(3 0 )-Ic-like, strA, strB], resistance genes related to folate metabolism (dfrA12, dfrA14-like), fluoroquinolones (qnrS1), sulphonamides (sul1, sul2, sul3), tetracyclines [tet(A)], phenicols (floR-like) and macrolides [mph(A)]. The number of acquired antibiotic resistance genes was significantly greater in ST131 than non-ST131 strains (P " 0.003) ( Figure S3A ). However, the number of resistance genes did not vary significantly across ST131 clades ( Figure S3C ).
No carbapenemase genes were identified. In one strain (MER-100), resistance to ceftazidime (but not ceftriaxone) was not clearly explained by resistance gene profiling, with no b-lactamase genes identified, although an altered #35 box (TTGACA) was found in its promoter, which has been associated with overexpression of the ampC promoter. 35 A single strain (MER-86) demonstrated resistance to ertapenem and was found to have disruption in ompF, which has been associated 
b-Lactamases
The predominant ESBL genes identified were bla CTX-M , seen in 80.0% (56/70) of isolates. The presence of bla CTX-M was strongly associated with ST131; 95% of ST131 possessed bla CTX-M ESBLs, compared with only 56% of non-ST131 (P , 0.001) (Table S1 ). These were either from CTX-M group 9 [bla CTX-M-14 (n " 8) , bla CTX-M-27 (n " 14)] or CTX-M group 1 [bla CTX-M-15 (n " 31) , bla CTX-M-55 (n " 3)], with the majority bla CTX-M-15 (44.3%). Clade C1 ST131 (n " 13) were associated with bla CTX-M-14 (n " 4) and bla CTX-M-27 (n " 9), whereas bla CTX-M-15 predominated in clade C2 (95.7%; 22/23) ( Figure S3B ). ESBL genes found in non-ST131 strains included bla CTX-M-15 (n " 7; ST12, ST95, ST648, ST973 and ST1193), bla CTX-M-14 (n " 3; ST10, ST69 and ST4702), and bla CTX-M-27 (n " 1; ST10).
The second most common group of b-lactamases with the ability to hydrolyse 3GCs were acquired AmpC b-lactamase genes, found in 17.1% (12/70). Acquired AmpC-producers were most frequently seen in strains from Brisbane (5/13, 38%), and Singapore (7/44, 15.9%), but none was detected in a smaller sample of patients from Melbourne or Auckland. The presence of acquired AmpC was not clearly associated with specific STs, but was more common in non-ST131 strains (37.0% versus 4.7%; P , 0.001). These were predominantly bla CMY-2 , although a single strain carried bla DHA-1 . A single clade C2 ST131 strain from Singapore possessed bla CMY-2 (in association with bla CTX-M-15 ) (Figure 2) . The genetic context of bla CMY-2 in five strains from Singapore showed homology with a plasmid (GenBank: LC019731) identified in Klebsiella pneumoniae from Taiwan ( Figure S4 ). bla CMY-2 located within an IncI1 plasmid backbone from two strains isolated in Australia was similar to a plasmid (pS10584; GenBank: KX058576.1) identified in Salmonella enterica from a food source in China ( Figure S5 ). ISEcp1 was identified in all but two of the E. coli strains carrying bla CMY-2 , with these associated with IS1294 and a truncated ISEcp1 ( Figure S5 ). Although bla CMY-2 are usually acquired on plasmids, in four strains {three from Australia [MER-2 (ST963), MER-4 (ST963), MER-43 (ST38)] and one from Singapore [MER-99 (ST93)]} there was evidence to suggest chromosomal integration based on flanking genes ( Figure S6 ). However, owing to repetitive regions surrounding the bla CMY-2 region, the complete context could not be ascertained in all isolates using short-read sequencing alone. A single strain (MER-89) possessed bla LAP-2 , and two (MER-86 and MER-110) carried both bla CTX-M and bla CMY .
Further details of the genetic context of bla CMY-2 and bla DHA-1 can be found in Figures S4-S7 .
Fluoroquinolone resistance genes
Acquired quinolone resistance genes (i.e. those not mediated by SNPs in regions associated with quinolone resistance) were seen in 11% (8/70) of strains. These genes included qnrS1, qnrB4, qnrB66-like, oqxA or aac(6 0 )Ib-cr. The presence of these genes was more commonly seen in non-ST131 than ST131 (22% versus 5%; P " 0.025). In some strains (e.g. MER-34, MER-26) phenotypic ciprofloxacin resistance was not evident despite the presence of acquired resistance genes, although these genes usually only confer low-level fluoroquinolone resistance in the absence of additional mechanisms.
All clade C strains [and a single clade A strain (MER-42)] were identical to the EC958 reference strain with respect to mutations in parC and gyrA (Tables S2 and S3 ). Phenotypic ciprofloxacin resistance was largely congruent with the presence of SNPs in parC and gyrA known to be associated with fluoroquinolone resistance, or the presence of acquired quinolone-resistance determinants. 37 Certain gyrA SNPs (e.g. 83L) were not by themselves associated with phenotypic ciprofloxacin resistance unless accompanied by additional SNPs (e.g. 87N or 87Y) (Table S3 ).
Sulphonamide and folate pathway resistance genes
Sulphonamide resistance genes (sul1, sul2 or sul3) were common, and present in 69% (48/70) of strains, as were folate synthesis pathway (e.g. trimethoprim) resistance genes (54%, 38/70), such as dfrA1, dfrA7, dfrA12, dfr14 and dfrA17. The presence of sulphonamide resistance and trimethoprim resistance genes was more common in ST131 (81% versus 48%, P " 0.004, and 74% versus 22%, P , 0.001, respectively).
Other resistance genes
The presence of aminoglycoside-modifying enzymes (AMEs) was common (seen in 76% of strains) and was encountered more frequently in ST131 (86% versus 59%; P " 0.011).
Genes mediating resistance to tetracyclines [specifically tet(A) and tet(B)] were seen in 56% (39/70) of strains, but were equally distributed between ST131 and non-ST131. Other frequently identified resistance genes included those mediating resistance to chloramphenicol (e.g. catA, florR) or macrolides [e.g. mph(A)].
Plasmids
The majority of plasmid replicon types were identified as IncF. IncF-type plasmids were closely associated with bla CTX-M . Almost all (53/55, 96.4%) E. coli with bla CTX-M also carried IncF-type plasmids, whereas only 53.3% of strains without bla CTX-M carried plasmids typed as IncF. According to the PubMLST scheme (www. pubmlst.org/plasmid), plasmids seen in clade C1 ST131 were mainly IncF plasmid type F1:A2:B20 (76.9%), with the remainder IncF-type F1:A2:B-or IncI1 types (ST79 or unknown ST). Amongst clade C2 ST131, IncF-types F31:A4:B1 or F36:A4:B1 were most common (22.7% and 27.3%, respectively), with IncF-type F2:A1:B-plasmids only seen in 18.2% (Figure 2 ). Only three clade C2 strains contained IncI1 or IncN plasmids. The presence of bla CMY-2 was associated with IncI1-type plasmids (unless chromosomally integrated). In a single strain, bla DHA-1 was located within an IncF-type plasmid ( Figure S7 ). However, given the limitations of reconstructing plasmids from short-read data alone, the location of b-lactamase genes within specific plasmids remains uncertain. A full summary of plasmid replicon types can be found in the Supplementary data.
Discussion
This prospective collection of ESBL-and p-AmpC-producing E. coli bloodstream isolates provides insight into the current clinical and molecular epidemiology of these infections within Australia, New Zealand and Singapore. The clear predominance of ST131 carrying CTX-M-type ESBLs is striking and reflects how this pandemic clone has emerged as a highly successful human pathogen. As has been described elsewhere, CTX-M-type ESBLs have now displaced TEMor SHV-type ESBLs in many parts of the world, 10, 38 and the latter were not seen in this contemporary collection of E. coli bloodstream isolates. It is also notable that the majority of cases were community associated, with their origin from the urinary tract and in patients over the age of 65 years. An increasing proportion of infections caused by ESBL-producing E. coli are reported as being community acquired. 39 Our study would suggest a community reservoir for 3GC-R E. coli, including CTX-M-producing ST131 (65% of which were associated with BSI in patients without any recent healthcare exposure). This contrasts to previous decades, following the first description of ESBLs, where nosocomial acquisition was common and TEM-and SHV-type EBSLs predominated. 4 Different b-lactamase genes were associated with certain E. coli lineages; bla CTX-M-15 was largely restricted to the C2 clade amongst ST131, whereas bla CTX-M-27 and bla CTX-M-14 were found in clade C1, which is consistent with previous studies. 8, 40 Within ST131, clades C1/H30-R and C2/H30-Rx are globally disseminated, and have not demonstrated clear geographical clustering, 8 although within some regions limited clonal expansion has occurred. 40 The global prevalence of bla CTX-M-15 has increased in most countries over recent years, and dominates in most regions, although group 9 variants (including bla CTX-M-14 ) are increasingly common in areas such as China, South-East Asia, Korea, Japan and Spain. 41 A second notable finding is the emerging prevalence of 3GC-R E. coli with acquired AmpC as a cause of BSIs; these were the second most commonly encountered broad-spectrum b-lactamase after CTX-M-type ESBLs in this cohort. Having been previously under-appreciated, p-AmpC enzymes (particularly bla CMY-2 ) are increasingly recognized as a prominent mediator of resistance in E. coli, and have been described in many parts of the world in both animal-and human-derived strains. [42] [43] [44] [45] [46] This is of clinical relevance because, despite isolates often testing susceptible WGS of ESBL-or AmpC-producing E. coli JAC in vitro to piperacillin/tazobactam, AmpC (Ambler class C) enzymes may be less efficiently inhibited than class A b-lactamases.
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Most clinical laboratories are unable to reliably identify p-AmpC enzymes in 3GC-R Enterobacteriaceae, which may have consequences for the reliability of piperacillin/tazobactam. In this cohort, p-AmpC (mainly bla CMY-2 ) were not associated with ST131 or any other ST. Previous studies have demonstrated the predominant p-AmpC enzyme amongst E. coli to be CMY-2, 42, 45, 48 with evidence that bla CMY-2 has been mobilized from the Citrobacter freundii chromosome in association with ISEcp1. 49 IncF-type plasmids have a host range that is limited to Enterobacteriaceae and contribute to bacterial fitness via antibiotic resistance and virulence determinants. 50 These plasmids have been associated with the rapid emergence and global spread of bla CTX-M-15 , as well as genes encoding resistance to aminoglycosides and fluoroquinolones [e.g. aac(6 0 )-Ib-cr, qnr, armA, rmtB]. 50, 51 Similar patterns were also seen in this study, where the majority of plasmids were of IncF type. There was an association between bla CTX-M-15 , bla OXA-1 , as well as the AMEs aac(3)-IIa and aac(6 0 )-Ib-cr in clade C2 ST131 carrying IncF plasmids, the majority of which came from patients in Singapore.
Previous work, mainly including isolates from North America, suggested that the H30-R/C1 clade of ST131 most commonly carries IncF-type F1:A2:B20 plasmids and the H30-Rx/C2 clade is associated with IncF-type F2:A1:B-plasmids. [17] [18] [19] In this cohort, plasmid types were associated with different sublineages of ST131. For instance, IncF-type F31:A4:B1 or F36:A4:B1 plasmids were most frequently seen in clade C2, whereas IncF-type F2:A1:B-were only seen in a single clade C1 strain. These variations may reflect sampling from different geographical locations, rather than associations with specific E. coli lineages.
This study has some limitations. Enrolment into the clinical trial required susceptibility to piperacillin/tazobactam at the local testing laboratory, and therefore bias may exist in the selection of strains. In addition, as enrolment of patients into a clinical trial may preclude those with severe comorbidities or early mortality (prior to randomization), it is possible that the E. coli were obtained from patients with less severe disease, which may be associated with less virulent strains. The limitations of short-read sequencing data to reconstruct plasmid structures 52 are also acknowledged.
Conclusions
In this analysis of 3GC-R E. coli causing BSI in patients from Singapore, Australia and New Zealand, a clear predominance of fluoroquinolone-resistant clade C1/C2 ST131 was observed. The majority of 3GC-R E. coli carried CTX-M-type ESBLs in association with IncF-type plasmids. The most common clinical source of BSI was community-associated urinary tract infections, consistent with a potential reservoir of these strains outside the healthcare environment. We also observed a significant proportion of non-ST131 strains carrying bla CMY-2 , which present additional challenges for laboratory detection and treatment.
